CytoSorbents Targets 2026 Breakeven: What it Means for MedTech ETFs

CytoSorbents has officially outlined its financial and regulatory roadmap, targeting operating cash flow breakeven by the second half of 2026. This strategic update comes as the company prepares for the DrugSorb-ATR de novo submission, which is now scheduled for late 2026 or early 2027. For market participants tracking the medical technology sector, this timeline provides a clear but extended window for the company's most anticipated product. The primary commercial signal…